Clinical Trial

Big4Bio and BYTE51 Announce Partnership at 2025 BIO International Convention to Make Life Sciences Intelligence Accessible to All

Collaboration will enable start-ups and other growing organizations to make better decisions, more quickly and cost-effectively BOSTON, June 16, 2025…

6 months ago

Axio BioPharma Expands Advisory Board with Leaders in Biologics Development and Manufacturing

Seasoned Executives Join to Support AI-Driven Growth in U.S.-Based Biomanufacturing MADISON, Wis., June 16, 2025 /PRNewswire/ -- Axio BioPharma Inc., a…

6 months ago

Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy

First Patients Expected to be Enrolled This MonthHalifax, Nova Scotia--(Newsfile Corp. - June 16, 2025) - Sona Nanotech Inc. (CSE:…

6 months ago

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced…

6 months ago

RayStation used for pioneering clinical milestone at Helsinki University Hospital – first treatment with accelerator-based BNCT in Europe

STOCKHOLM, June 16, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce that RayStation®*, its advanced treatment planning…

6 months ago

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for…

6 months ago

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

D-bal-max D-Bal MAX Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced athletic performance and muscle growth,…

6 months ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data…

6 months ago